Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 1254 results for criteria

  1. Osimertinib for adjuvant treatment of EGFR mutation-positive stage 1A2 or 1A3 non-small-cell lung cancer after complete tumour resection

    Awaiting development Reference number: GID-TA12457 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Vonaprument for treating geographic atrophy caused by age-related macular degeneration

    Awaiting development Reference number: GID-TA12454 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tanruprubart for treating Guillain–Barre syndrome in people 12 years and over

    Awaiting development Reference number: GID-TA12453 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Inavolisib with pertuzumab–trastuzumab for maintenance treatment of PIK3CA-mutated HER2-positive advanced breast cancer after induction chemotherapy

    Awaiting development Reference number: GID-TA12441 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Zilovertamab vedotin in combination for treating relapsed or refractory diffuse large B-cell lymphoma

    Awaiting development Reference number: GID-TA12458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Xanomeline tartrate–trospium chloride for treating psychosis associated with Alzheimer's disease

    Awaiting development Reference number: GID-TA12460 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Imlunestrant for adjuvant treatment of ER-positive, HER2-negative early breast cancer with increased risk of recurrence

    Awaiting development Reference number: GID-TA12459 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Venglustat for treating Fabry disease

    Awaiting development Reference number: GID-TA12452 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Orforglipron for managing overweight and obesity in people 12 to 17 years

    Awaiting development Reference number: GID-TA12451 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Divarasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

    Awaiting development Reference number: GID-TA12450 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Niraparib for treating newly diagnosed unmethylated glioblastoma

    Awaiting development Reference number: GID-TA12449 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Sacituzumab tirumotecan for treating endometrial cancer after platinum-based chemotherapy and immunotherapy

    Awaiting development Reference number: GID-TA12448 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Cagrilintide–semaglutide for managing overweight and obesity

    Awaiting development Reference number: GID-TA12443 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Ivonescimab for untreated metastatic non-small-cell lung cancer with high PD-L1 expression

    Awaiting development Reference number: GID-TA12444 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Lutikizumab for treating moderate to severe hidradenitis suppurativa in people 12 years and over

    Awaiting development Reference number: GID-TA12446 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development